Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

European Lung Cancer Congress 2020

15 - 18 Apr 2020

-, Geneva, Switzerland

Background of the KEYNOTE-158 trial for pembrolizumab in advanced mesothelioma

Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA

Background of the KEYNOTE-158 trial for pembrolizumab in advanced mesothelioma ( Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA )

Preclinical models for small-cell lung cancer

Prof Anton Berns - Netherlands Cancer Institute, Amsterdam, Netherlands

Preclinical models for small-cell lung cancer ( Prof Anton Berns - Netherlands Cancer Institute, Amsterdam, Netherlands )

Do immune checkpoint inhibitors work in EGFR mutant lung cancer?

Dr Edward Garon - UCLA Medical Center, Santa Monica, USA

Do immune checkpoint inhibitors work in EGFR mutant lung cancer? ( Dr Edward Garon - UCLA Medical Center, Santa Monica, USA )

Managing toxicities associated with immune-checkpoint inhibitors

Prof Olivier Lambotte - Hôpitaux de Paris, Paris, France

Managing toxicities associated with immune-checkpoint inhibitors ( Prof Olivier Lambotte - Hôpitaux de Paris, Paris, France )

New oncogenic drivers in NSCLC

Prof Egbert Smit - Netherlands Cancer Institute, Amsterdam, Netherlands

New oncogenic drivers in NSCLC ( Prof Egbert Smit - Netherlands Cancer Institute, Amsterdam, Netherlands )

The potential of KRAS inhibitors for non-small-cell lung cancer

Prof Reinhard Büttner - University Hospital Cologne, Cologne, Germany

The potential of KRAS inhibitors for non-small-cell lung cancer ( Prof Reinhard Büttner - University Hospital Cologne, Cologne, Germany )

More from ecancer